Cell Impact AB (CI) AI Stock Analysis

• Market Cap: kr41.20M
• Dividend Yield: N/A
• Average Volume (3M): 26.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.94
• Revenue Growth: 1.01%
• EPS Growth: 65.54%
• Country: SE
• Employees: 41
• Sector: Industrials
• Sector Strength: 82
• Industry: Manufacturing - Metal Fabrication
• EPS (TTM): -0.02
• Shares Outstanding: 2,657,847,400
• 10 Day Avg. Volume: 17,389,675
• 30 Day Avg. Volume: 26,104,049
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: kr0.00 ▼(-100.00% Downside)

Cell Impact AB's overall stock score is significantly impacted by its weak financial performance and bearish technical analysis. The company's declining revenues, increasing losses, and negative cash flows are major concerns. Additionally, technical indicators suggest potential further downside. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield, further weighing down the score.

Cell Impact AB Business Overview & Revenue Model

Company Description

Cell Impact AB (publ) manufactures and sells bipolar flow plates for hydrogen fuel cells in Sweden and internationally. The company offers plates with and precise flow patterns. It serves hydrogen fuel cells producers. The company was incorporated in 1999 and is based in Karlskoga, Sweden.

How the Company Makes Money

Cell Impact AB makes money primarily through the sale of its highly specialized flow plates to manufacturers of fuel cells and electrolyzers. The company's revenue model is based on the production and sale of these components, which are critical for the function and efficiency of hydrogen-powered systems. Key revenue streams include direct sales to OEMs (Original Equipment Manufacturers) in the automotive and energy sectors, as well as strategic partnerships with companies involved in renewable energy projects. Additionally, Cell Impact may engage in collaborative development projects and licensing agreements to further monetize its proprietary manufacturing technologies and designs.

Cell Impact AB Financial Statement Overview

Summary

Cell Impact AB has a declining revenue trend and widening losses, as indicated by the income statement. The balance sheet shows strong equity but increasing net debt, while negative operating and free cash flows raise liquidity concerns.

Income Statement

Cell Impact AB's income statement shows a declining revenue trend with a significant drop from 2022 to 2023, followed by a further decrease in 2024. The gross profit margin has been decreasing over the years, indicating cost pressures. Negative EBIT and net profit margins reflect ongoing unprofitability, with widening losses over the years. These factors contribute to a moderate score as the company struggles with profitability and revenue growth.

Balance Sheet

The balance sheet shows strong equity levels compared to total assets, indicating stability. The debt-to-equity ratio is low, suggesting conservative leverage. However, a declining stockholder's equity and increasing net debt in 2024 raise concerns about financial sustainability. Despite the strong equity ratio, these negative trends affect the overall stability score.

Cash Flow

Cell Impact AB's cash flow statement highlights negative operating and free cash flows, with deteriorating free cash flow over the years. While the company has managed significant financing activities in the past, the inability to generate positive operating cash flow remains a significant concern. The free cash flow to net income ratio is negative, underscoring cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.33M	47.26M	76.81M	71.35M	29.31M
Gross Profit	5.42M	25.45M	36.94M	34.88M	19.14M
EBITDA	-66.52M	-94.65M	-86.22M	-68.84M	-37.29M
Net Income	-100.43M	-121.40M	-104.22M	-79.85M	-44.26M
Balance Sheet
Total Assets	261.25M	381.93M	401.51M	238.72M	242.88M
Cash, Cash Equivalents and Short-Term Investments	20.39M	99.89M	164.67M	28.56M	151.93M
Total Debt	30.92M	42.75M	44.70M	19.51M	21.98M
Total Liabilities	42.16M	78.56M	77.17M	96.10M	40.99M
Stockholders Equity	219.08M	303.37M	324.35M	142.63M	201.89M
Cash Flow
Free Cash Flow	-76.66M	-152.75M	-174.32M	-140.39M	-69.64M
Operating Cash Flow	-62.23M	-100.97M	-105.93M	-86.08M	-47.59M
Investing Cash Flow	-14.43M	-51.78M	-68.40M	-54.32M	-21.96M
Financing Cash Flow	-2.84M	88.09M	310.47M	17.01M	204.57M

Cell Impact AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.76 is Neutral, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CI.

Cell Impact AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	58 Neutral	HK$13.91B	4.82	-3.70%	5.62%	2.15%	-62.33%
CI	42 Neutral	kr41.20M	―		―	1.01%	65.54%
PCELF	―	$175.78M	―	-1.36%	―	―	―
8Y1	―	€11.13M	―	-31.89%	―	―	―
9G8	―	€51.84M	32.08	3.44%	―	―	―
BO6	―	€6.48M	―	-103.44%	―	―	―
7X9	―	€142.30M	―	-54.63%	―	―	―